ARATANA THERAPEUTICS, INC. License Agreements
12 Contracts & Agreements
- First Amendment, dated April 26, 2019, to the Amended and Restated Exclusive License, Development and Commercialization Agreement, dated July 5, 2018, by and between Aratana... (Filed With SEC on April 26, 2019)
- Amended and Restated Exclusive License, Development and Commercialization Agreement, dated July 5, 2018, between the Company and Pacira Pharmaceuticals, Inc (Filed With SEC on August 3, 2018)
- Exhibit 10.14(c) Second Amendment to the Exclusive IP License Agreement for RQ-00000007 between Aratana Therapeutics Inc. and RaQualia Pharma Inc. (Filed With SEC on March 14, 2017)
- Exhibit 10.13(c) Second Amendment to the Exclusive IP License Agreement for RQ-00000005 between Aratana Therapeutics Inc. and RaQualia Pharma Inc. (Filed With SEC on March 14, 2017)
- EXCLUSIVE IP LICENSE AGREEMENTFOR RQ-00000007 (Filed With SEC on June 6, 2013)
- EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005 (Filed With SEC on June 6, 2013)
- EXCLUSIVE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on April 11, 2013)
- First Amendment to the Exclusive IP License Agreement for RQ-00000007 between Aratana Therapeutics Inc. and RaQualia Pharma Inc. (Filed With SEC on April 11, 2013)
- EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000007 (Filed With SEC on April 11, 2013)
- First Amendment to the Exclusive IP License Agreement for RQ-00000005 between Aratana Therapeutics Inc. and RaQualia Pharma Inc. (Filed With SEC on April 11, 2013)
- EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005 (Filed With SEC on April 11, 2013)
- EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005 (Filed With SEC on March 20, 2013)
